BR112018007681A2 - pharmaceutical combination of an atypical antipsychotic and an nmda modulator for the treatment of schizophrenia, bipolar disorder, cognitive impairment and major depressive disorder - Google Patents
pharmaceutical combination of an atypical antipsychotic and an nmda modulator for the treatment of schizophrenia, bipolar disorder, cognitive impairment and major depressive disorderInfo
- Publication number
- BR112018007681A2 BR112018007681A2 BR112018007681-3A BR112018007681A BR112018007681A2 BR 112018007681 A2 BR112018007681 A2 BR 112018007681A2 BR 112018007681 A BR112018007681 A BR 112018007681A BR 112018007681 A2 BR112018007681 A2 BR 112018007681A2
- Authority
- BR
- Brazil
- Prior art keywords
- amino
- pyrrolidine
- carbonyl
- hydroxy
- carboxamide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562242633P | 2015-10-16 | 2015-10-16 | |
| US62/242,633 | 2015-10-16 | ||
| PCT/US2016/057071 WO2017066590A1 (en) | 2015-10-16 | 2016-10-14 | Pharmaceutical combination of an atypical antipsychotic and an nmda modulator for the treatment of schizophrenia,bipolar disorder, cognitive impairment and major depressive disorder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018007681A2 true BR112018007681A2 (en) | 2018-11-06 |
Family
ID=57178579
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018007681-3A BR112018007681A2 (en) | 2015-10-16 | 2016-10-14 | pharmaceutical combination of an atypical antipsychotic and an nmda modulator for the treatment of schizophrenia, bipolar disorder, cognitive impairment and major depressive disorder |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20180325893A1 (enExample) |
| EP (1) | EP3362080A1 (enExample) |
| JP (2) | JP2018530593A (enExample) |
| KR (1) | KR20180102052A (enExample) |
| CN (1) | CN108601814A (enExample) |
| AU (2) | AU2016340080A1 (enExample) |
| BR (1) | BR112018007681A2 (enExample) |
| CA (1) | CA3002070A1 (enExample) |
| MX (1) | MX2018004553A (enExample) |
| WO (1) | WO2017066590A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017100599A1 (en) | 2015-12-09 | 2017-06-15 | Luc Therapeutics | Thienopyrimidinone nmda receptor modulators and uses thereof |
| ES2821010T3 (es) | 2015-12-09 | 2021-04-23 | Cadent Therapeutics Inc | Moduladores heteroaromáticos del receptor NMDA y usos de los mismos |
| AU2017382339B2 (en) | 2016-12-22 | 2024-02-15 | Novartis Ag | NMDA receptor modulators and uses thereof |
| US20200199173A1 (en) * | 2017-07-28 | 2020-06-25 | Naurex, Inc. | Process and intermediates for synthesis of peptide compounds |
| BR112020009310A2 (pt) | 2017-11-14 | 2020-10-13 | Sk Biopharmaceuticals Co., Ltd. | combinação e composição farmacêutica para a prevenção, alívio ou tratamento da esquizofrenia. |
| DK3505157T3 (da) | 2017-12-29 | 2022-02-28 | Celon Pharma Sa | Tørpulver-ketaminsammensætning til pulmonal indgivelse ved behandlingsresistent depression |
| PT3830092T (pt) | 2018-08-03 | 2023-07-25 | Novartis Ag | Moduladores do recetor nmda heteroaromáticos e suas utilizações |
| US20220024976A1 (en) * | 2019-01-11 | 2022-01-27 | Naurex Inc. | Salt and crystalline forms of rapastinel |
| KR20210060843A (ko) | 2019-11-19 | 2021-05-27 | 뉴트라팜주식회사 | 기억력 및 인지기능 개선, 조현병 예방, 치료 또는 개선용 조성물 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5902815A (en) * | 1996-09-03 | 1999-05-11 | Washington University | Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction |
| KR20040105740A (ko) * | 2002-02-25 | 2004-12-16 | 엘란 파마슈티칼스, 인크. | 염증 치료제의 투여 방법 |
| WO2006066121A2 (en) * | 2004-12-16 | 2006-06-22 | Janssen Pharmaceutica N.V. | Combination of a glycine transporter (glyt1) inhibitor and an antipsychotic for the treatment of symptoms of schizophrenia as well as its preparation and use thereof |
| JP5838021B2 (ja) * | 2005-04-15 | 2015-12-24 | マクロジェニクス，インコーポレーテッド | 共有結合型ダイアボディとその使用 |
| EP2485751B1 (en) * | 2009-10-05 | 2014-05-21 | Northwestern University | GLYX-13 for use in a method of treating refractory depression |
| KR101692275B1 (ko) * | 2010-02-11 | 2017-01-04 | 노오쓰웨스턴 유니버시티 | ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도 |
| SG10201501050RA (en) * | 2010-02-11 | 2015-04-29 | Univ Northwestern | Secondary Structure Stabilized NMDA Receptor Modulators And Uses Thereof |
| US9737531B2 (en) * | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
| MX357761B (es) * | 2011-04-27 | 2018-07-23 | Univ Northwestern | Métodos para tratar la enfermedad de alzheimer, enfermedad de huntington, autismo u otros trastornos. |
| WO2013080046A1 (en) * | 2011-12-02 | 2013-06-06 | Dainippon Sumitomo Pharma Co., Ltd. | Lurasidone novel dosage regimens and use thereof for the treatment, prevention, and/or management of at least one cns disorder |
| EP2906722A4 (en) * | 2012-10-12 | 2016-07-20 | Univ Northwestern | METHOD FOR IDENTIFYING COMPOUNDS FOR THE TREATMENT OF DEPRESSIONS AND RELATED DISEASES |
| US20160345855A1 (en) * | 2013-12-13 | 2016-12-01 | Northwestern University | Methods of treating brain disorders or identifying biomarkers related thereto |
| BR112016025910A8 (pt) * | 2014-05-06 | 2021-07-13 | Univ Northwestern | uso de uma quantidade eficaz de glyx-13, uso de glyx-13 e um antagonista de nmdar e composição farmaceuticamente aceitável compreendendo os mesmos |
| KR20170040351A (ko) * | 2014-08-14 | 2017-04-12 | 노렉스, 인크. | Nmda 조절인자를 사용하여 우울증을 치료하는 방법 |
-
2016
- 2016-10-14 KR KR1020187013668A patent/KR20180102052A/ko not_active Ceased
- 2016-10-14 US US15/773,084 patent/US20180325893A1/en not_active Abandoned
- 2016-10-14 CA CA3002070A patent/CA3002070A1/en not_active Abandoned
- 2016-10-14 WO PCT/US2016/057071 patent/WO2017066590A1/en not_active Ceased
- 2016-10-14 EP EP16784754.0A patent/EP3362080A1/en not_active Withdrawn
- 2016-10-14 JP JP2018519482A patent/JP2018530593A/ja active Pending
- 2016-10-14 BR BR112018007681-3A patent/BR112018007681A2/en not_active IP Right Cessation
- 2016-10-14 CN CN201680064997.4A patent/CN108601814A/zh active Pending
- 2016-10-14 AU AU2016340080A patent/AU2016340080A1/en not_active Abandoned
- 2016-10-14 MX MX2018004553A patent/MX2018004553A/es unknown
-
2022
- 2022-07-04 JP JP2022107539A patent/JP2022140441A/ja active Pending
-
2023
- 2023-08-17 AU AU2023216827A patent/AU2023216827A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| RU2018116882A3 (enExample) | 2020-02-18 |
| US20180325893A1 (en) | 2018-11-15 |
| EP3362080A1 (en) | 2018-08-22 |
| CA3002070A1 (en) | 2017-04-20 |
| JP2022140441A (ja) | 2022-09-26 |
| KR20180102052A (ko) | 2018-09-14 |
| CN108601814A (zh) | 2018-09-28 |
| AU2016340080A1 (en) | 2018-05-10 |
| AU2023216827A1 (en) | 2023-09-07 |
| JP2018530593A (ja) | 2018-10-18 |
| MX2018004553A (es) | 2019-04-15 |
| WO2017066590A1 (en) | 2017-04-20 |
| RU2018116882A (ru) | 2019-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2023216827A1 (en) | Pharmaceutical combination of an atypical antipsychotic and an NMDA modulator for the treatment of schizophrenia, bipolar disorder, cognitive impairment and major depressive disorder | |
| AU2019204073B2 (en) | NMDA receptor modulators and uses thereof | |
| US20230192693A1 (en) | Spiro-lactam nmda modulators and methods of using same | |
| US10195179B2 (en) | Spiro-lactam NMDA receptor modulators and uses thereof | |
| US9932347B2 (en) | Spiro-lactam NMDA receptor modulators and uses thereof | |
| US20220151992A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| CA2947976A1 (en) | Combinations of nmdar modulating compounds | |
| JP2020176124A (ja) | Ｎ−メチル−ｄ−アスパラギン酸受容体モジュレーターならびにその製造方法及び使用方法 | |
| RU2802972C2 (ru) | Фармацевтическая комбинация атипичного антипсихотика и модулятора nmda для лечения шизофрении, биполярного расстройства, когнитивного нарушения и клинической депрессии | |
| EA042012B1 (ru) | Спиролактамовые модуляторы nmda-рецептора и их применение |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
| B08G | Application fees: restoration [chapter 8.7 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 9A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2854 DE 16-09-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |